XML 105 R74.htm IDEA: XBRL DOCUMENT v3.21.1
Collaborative and Other Relationships - Collaborations (Details)
$ / shares in Units, shares in Millions, $ in Millions
 1 Months Ended 3 Months Ended
Nov. 30, 2020
USD ($)
$ / shares
shares
Feb. 29, 2020
USD ($)
$ / shares
shares
Mar. 31, 2021
USD ($)
product
$ / shares
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Jan. 31, 2020
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Loss on equity method investment     $ (18.2) $ (16.8)    
Eisai            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Number of product candidates | product     2      
Expense Incurred By Collaboration     $ 55.5 43.5    
Expense reflected within statements of income     $ 27.7 21.8    
Percentage of future development costs related to Eisai     45.00%      
Loss on research and development contracts terminated with Eisai         $ 45.0  
Loss on equity method investment     $ 33.8      
Denali Therapeutics            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Global Licensing Collaboration Agreement, Amount, Shares Purchased     $ 465.0      
Global Licensing Collaboration Agreement, Shares Purchased Per Share | $ / shares     $ 34.94      
Upfront and milestone payments made to collaborative partner     $ 560.0      
Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments     1,100.0      
Research and development expense     $ 41.3      
Samsung Bioepis            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Upfront and milestone payments made to collaborative partner       100.0    
Collaboration agreement term     5 years      
Research and development expense       63.0    
Prepaid research and development expenses           $ 37.0
Sage Therapeutics Inc.            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Global Licensing Collaboration Agreement, Amount, Shares Purchased $ 650.0          
Global Licensing Collaboration Agreement, Shares, Purchased | shares 6.2          
Upfront and milestone payments made to collaborative partner $ 875.0          
Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments 1,600.0          
Research and development expense $ 209.0          
Global Licensing Collaboration Agreement, Purchase Price Per Share | $ / shares $ 104.14          
Sangamo Therapeutics, Inc. Agreement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Global Licensing Collaboration Agreement, Amount, Shares Purchased   $ 225.0        
Global Licensing Collaboration Agreement, Shares, Purchased | shares   24.0        
Global Licensing Collaboration Agreement, Shares Purchased Per Share | $ / shares   $ 9.21        
Upfront and milestone payments made to collaborative partner   $ 125.0        
Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments   2,400.0        
Global Licensing Collaboration Agreement, Payment, Selection of Targets   80.0        
Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones   1,900.0        
Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones   380.0        
Research and development expense   $ 83.0        
Term of collaboration agreement     5 years      
Research and development | Eisai | Aducanumab            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Expense incurred by the collaboration     $ 47.0 19.1    
Expense reflected within statements of income     25.8 10.5    
Research and development | UCB Pharma S.A. [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Expense incurred by the collaboration     16.9 19.0    
Expense reflected within statements of income     8.4 9.5    
Selling, general and administrative | Eisai | BAN2401 and Elenbecestat            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Expense incurred by the collaboration     5.7 4.9    
Expense reflected within statements of income     2.9 2.4    
Selling, general and administrative | Eisai | Aducanumab            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Expense incurred by the collaboration     111.8 22.7    
Expense reflected within statements of income     $ 60.3 $ 12.3